Responsible for building corporate Program Management Office (PMO) as well leading Drug Development Program Management team for global Clinical Development programs. Transaction lead for acquisition of Phase 3 asset from Mallinckrodt for a Rare Disease.Therapeutic areas include Niemann Pick Type C, Cardiovascular Disease, Alzheimer’s and Dementia

Oversaw global R&D programs from early discovery research through mid-stage clinical development and planning of Phase III studies/product launch. Led the PM function at the Vertex San Diego site; established best practices and managed site portfolio. Therapeutic area focus on Respiratory and CNS including Cystic Fibrosis and Pain. Supervised a team of Ph.D. level program managers overseeing drug discovery and early development programs. • Managed discovery and early development teams that led to four (to date) drug products, KALYDECO™, ORKAMBI™, SYMDEKO™ and TRIKAFTA™, the first drugs in history to target the defective gene that causes Cystic Fibrosis. • Managed discovery & early to mid-stage drug development of multiple drug candidates in clinical development, including entire portfolio CFTR Modulators and company's first novel pain program, one of the first in the field selective sodium channel blockers.• Managed large external drug discovery and development collaborations with CRISPR Tx, & Moderna with a focus on mRNA and CRISPR therapeutics for Cystic Fibrosis and other rare diseases.• Lead Program and Alliance Manager for the 15 year duration of the Cystic Fibrosis Foundation research collaboration, resulting in Vertex’s portfolio of CF therapies, featured as a Harvard Business case study: https://www.hbs.edu/faculty/Pages/item.aspx?num=43020).• Created Oracle-based system for tracking project progress, enabling provision of resourcing metrics for multiple collaborations and internal programs. • Managed San Diego site external budget creation, mapping & forecasting.• Managed external pharmaceutical and nonprofit orphan disease collaborations, serving as primary point of contact for all involved parties. • Established best practices for stage gate, documentation, planning, and reporting. Developed standard dossier for development candidate nomination that became the foundation for regulatory filing summaries and investigator brochures.

Volunteer Leadership Initiative Chair 2008

Project Manager Managed relationships and projects associated with external drug discovery collaborations involving major pharmaceutical companies, including Merck, Pfizer, BMS, J&J, Allergan, Glaxo, Lilly, Organon, and Senomyx, and nonprofit foundations, such as the Cystic Fibrosis Foundation, Huntington’s Disease Foundation, and Cure SMA (Spinal Muscular Atrophy).• Prepared for and led joint research meetings, steering committee meetings, and other collaborative meetings. • Partnered with leaders of global project teams to ensure projects’ execution aligned with strategies and goals. • Guided research groups through annual budget and forecasting process. Liaised with finance department to communicate project forecasts.• Managed successful asset transfer of Aurora-based assay development tools (including GFP, Beta lactamase, and custom voltage sensing dyes) to Invitrogen (aka Life Technologies), following acquisition of Aurora by Vertex Pharmaceuticals in 2001.Senior Research AssociateResearched membrane translocation sequence technology (MTS) for translocation of proteins into cells, contributing to NIH SBIR grant-funded project. • Developed UHTS-compatible (3456-well) biochemical assays for internal drug discovery and 3456-well kinase assays.• Transferred assays, methodologies, and screening hits/leads to external collaborators.Acquired by Vertex Pharmaceuticals in 2001

GPCR Assay Development. Lead scientist in developing HTS assays, Medchem screening, and secondary hit follow-up. Developed GPCR ligand-binding and reporter gene assays. Assay development and HTS for multiple programs in Ferring’s Fertility, Obesity and Pain franchises. Radiation safety officer for pharmacology labs at San Diego site.

Pre-clinical drug investigation of a novel chemotherapeutic agent, partnered with Collagenex Pharmaceuticals. Investigated the application of a chemically modified non-antimicrobial tetracycline (CMT-3) against metastatic prostate cancer.

Responsible for the research, development and troubleshooting of problem components and instrumentation related to the Ion Selective Electrode Diagnostic technology for the Baxter Stratus II and Lytening I immunology analyzers. QC testing. GMP/GLP certified.

Area of study focused on physical inorganic chemistry and included structural analysis by NMR spectroscopy, as well as electrochemistry, protein abstraction and purification. Thesis pertained to the purification and the physical and structural characterization of the Nitrophorin 1 Heme protein of Rhodnius Prolixus, the "kissing bug", in the absence of a crystal structure of the protein. This is one of the few known reversibly binding nitric oxide heme proteins that exist in nature. The result of the research gives insight into potential nitric oxide carrier and delivery systems.